Safety and Pharmacokinetics of ONC201 (dordaviprone) Administered Two Consecutive Days Per Week in Pediatric Patients with H3 K27M-mutant Glioma.
Yazmin Odia,Carl Koschmann,Nicholas A. Vitanza,Peter de Blank,Dolly Aguilera,Jeffrey Allen,Doured Daghistani,Matthew Hall,Ziad Khatib,Cassie Kline,Tobey Macdonald,Sabine Mueller, Shamia L. Faison,Joshua E. Allen,Odin J. Naderer,Samuel C. Ramage,Rohinton S. Tarapore,Susan Lynne Mcgovern,Soumen Khatua,Wafik Zaky,Sharon L. Gardner Neuro-Oncology（2024）
关键词
ONC201,dordaviprone,H3 K27M mutation,dose optimization
AI 理解论文
溯源树
样例
